Abstract
Today there is a growing wave of demands being placed upon the pharmaceutical industry to contribute to improved access to medicines for poor patients in the developing countries.1 This article aims to contribute to the development of a systematic approach and broad consensus about shared benchmarks for good corporate practices in this area. A consensus corridor on what constitutes an appropriate portfolio of␣corporate responsibilities for access to medicines – especially under conditions of ‘failing states’ and ‘market failure’2 – is not only in the interest of the world’s poor, but also of corporations that want to contribute to the solution of one of the most significant social problems of our time.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abbasi, K.: 1999, ‘Healthcare Strategy’, British Medical Journal 318, 933–1006
Anand, S., & K. HansonK. 2006. Disability-Adjusted Life Years: A Critical Review. In Anand, S., Peter, F., & Sen, A., (eds). Public Health, Ethics and Equity. Oxford: Oxford University Press
Attaran, A. 2004. How do Patents and Economic Policies Affect Access to Essential Medicines in Developing Countries? Health Affairs 23(3), 155–66
Baird, M. and S. Shetty: 2003, ‘Getting There How to Accelerate Progress Toward the Millennium Development Goals’, Finance & Development, 14–19. Article Available Online at http://www.imf.org/external/pubs/ft/fandd/2003/12/pdf/baird.pdf
Bate, R., R. Tren, L. Mooney and K. Boateng: 2006, ‘Tariffs, Corruption and Other Impediments to Medicinal Access in Developing Countries: Field Evidence’, Working Paper 130, American Enterprise Institute, Accessed 12 September 2008. http://www.aei.org/publications/pubID.24749/pub_detail.asp
Bates, R.: 2006, ‘Taxed to Death’, Foreign Policy
Beynon, K. & Porter, A., 2000. Valuing Pharmaceutical Companies: A Guide to the Assessment and Evaluation of Assets, Performance and Prospects. Cambridge: Woodhead
Buchholtz, A.K., Amason, A.C., & Rutherford, M.A., 1999. Beyond Resources. The Mediating Effect of Top Management Discretion and Value on Corporate Philanthropy. Business & Society 38(2), 167–187
Business and Human Rights Resource Center: www.business-humanrights.org/Home
Cagir, D.: 2005, ‘Agency Costs or Advertising? Corporate Donations for Tsunami Relief’, Claremont McKenna College Leadership Review 5, 90–109
Carroll, A.B. 1993. Business & Society. Ethics and Stakeholder Management. 2nd edt. Cincinnati: South-Western Publishing Co
Chen, S. and M. Ravallion: 2007, ‘Absolute Poverty Measures for the Developing World 1981–2004’, Proceedings of the National Academy of Science of United States of America 104(43), 16757 f. www.pnas.org/cgi/reprint/0702930104v1.pdf
Commission on Macroeconomics and Health: 2003, ‘Increasing Investments in Health Outcomes for the Poor’, 2nd Consultation, Geneva. www.who.int/macrohealth/events/health_for_poor/en/E_REPORT.pdf
Dahrendorf, R. 1959. Homo Sociologicus. Cologne: Opladen
Daniels, N., et al.: 2006, `Health and Inequality, or, Why Justice is Good for Our Health', in S. Anand, F. Peter and A. Sen (eds.), Public Health, Ethics and Equity (Oxford University Press, Oxford)
Danish Institute for Human Rights: ‘Guidelines for Compliance with the Right to Health of the Human Rights Compliance’, www.humanrights.dk
Department for International Development, Department of Health, Department of Trade and Industry: 2005, Increasing People’s Access to Essential Medicines in Developing Countries: A Framework for Good Practices in the Pharmaceutical Industry. A UK Government Policy Paper, London
Department of International Development, Department of Health et al.: 2004, Increasing Access to Essential Medicines in the Developing World. UK Government Policy and Plans. London
Donaldson, T., & Dunfee, T.E., 1999. Ties that Bind: A Social Contracts Approach to Business Ethics. Boston: Harvard Business School Press
Drèze, J., & Sen, A., 1989. Hunger and Public Action. Oxford: Clarendon Press
EU High Level Committee on Health: http://ec.europa.eu/health/ph_overview/Documents/ke02_en.pdf
Filmer, D., J. Hammer and L. Pritchett: 1999, Health Policy in Poor Countries: Weak Links in the Chain. World Bank Policy Research Working Paper No. 1874, Washington, DC
Friedman, M. 1962. Capitalism and Freedom (Fortieth Anniversary Edition). Chicago: The University of Chicago Press
Hambrick, D.C., & Mason, P.A., 1984. Upper Echelons: The organization as a reflection of its top managers. Academy of Management Review 9(2), 193–206
Hardin, G.: 1976, ‘The Tragedy of the Commons’, in M. D. Bayles (ed.), Ethics and Population (Schenkman Publishing Company Inc., Cambridge, Mass.)
Henkin, L.: 1999, ‘The Universal Declaration at 50 and the Challenges of Global Markets’, Brooklyn Journal of International Law XXV(1), 25
IFPMA: 2008, Principal Focus and Action of the Research-Based Pharmaceutical Industry in Contributing to Global Health (Mimeo), Geneva
Jones, G. R.: 2000, Personal Values and Corporate Philanthropy – A Theoretical Model for the Role Senior Executives’ Personal Values Play in Decisions Regarding Corporate Philanthropy. Flinders University of South Australia. School of Commerce Research Paper Series: 0023, December 2000
Leisinger, K. M.: 1985, ‘Health Policy for Least Developed Countries’, Basel. Available through the Novartis Foundation for Sustainable Development, www.novartisfoundation.org
Leisinger, K. M. 2007a. Capitalism with a Human Face. Journal of Corporate Citizenship 28, 113–132
Leisinger, K. M. 2007b. Corporate Philanthropy: The ‘Top of the Pyramid.’ Business and Society Review 112(3), 315–42
Leisinger, K. M.: Forthcoming, The Business Case for Corporate Responsibility (Novartis Foundation for Sustainable Development, Basel), www.novartisfoundation.org
Lerner, L.D., & Fryxell, G.E., 1994. CEO stakeholder attitudes and corporate social activity in the Fortune 500. Business & Society 33(1), 58-81
Lodge, G., & Wilson, C., 2006. A Corporate Solution to Global Poverty. How Multinationals can help the Poor and Invigorate their own Legitimacy. Princeton and Oxford: Princeton University Press
Luhmann, N.: 1996, in J. Bednarz and D. Baecker (eds.), Social Systems (Writing Science) (Stanford University Press, Stanford)
Manton, K. G. and X. Gu: 2001, ‘Changes in the Prevalence of Chronic Disability in the United States Black and Non-Black Population Above Age 65 from 1982 to 1999’, Proceedings of the National Academy of Sciences of United States of America 98(11), 6354–6359
Marmot, M. 2006. Social Causes of Social Inequalities in Health. In Anand, S., Peter, F., & Sen, A., (eds) Public Health, Ethics and Equity. Oxford: Oxford University Press
Maturana, H., & Vaerla, F. 1979. Autopoiesis and Cognition. Boston: Reidel
Médecins Sans Frontières: www.msf.org/search/index.cfm?searchCriteria=access+to+medicine
Milken Institute: 2007, An Unhealthy America: The Economic Burden of Chronic Disease – Charting a New Course to Save Lives and Increase Productivity and Economic Growth (Santa Monica)
Murray, C.J.L., 1994. Quantifying the burden of disease: The Technical Base for Disability-Adjusted Life Years. WHO. Bulletin of the World Health Organization, 72, 429–445
Myrdal, G. 1968. Asian Drama. An Inquiry into the Poverty of Nations. I. Harmondswortrh: Pelican
Narayan, D. et al.: 2000, Voices of the Poor. Can Anyone Hear Us? (Oxford University Press, Oxford/World Bank, Washington, DC)
Nikièma, B., S. Haddad and L. Potvin: 2008, ‘Women Bargaining to Seek Healthcare: Norms, Domestic Practices, and Implications in Rural Burkina Faso’, World Development 36(4), 608–624
Novartis Foundation for Sustainable Development: www.novartisfoundation.org
Nuffield Council on Bioethics: 2007, Public Health: Ethical Issues (London)
OECD: 2005, Health Data 2004 (OECD, Paris)
Oxfam: 2007, Investing for Life. Meeting Poor People’s Needs for Access to Medicines Through Responsible Business Practices. Oxfam Briefing Paper No. 109, London
Population Reference Bureau: 2007, ‘World Population Data Sheet’, www.prb.org/Publications/Datasheets/2007/2007WorldPopulationDataSheet.aspx
Riegler, A.: 2005, ‘Editorial. The Constructivist Challenge', Constructivist Foundation 1(1), 1–8
Sachs J.D. 2008a. Common Wealth. Economics for a Crowded Planet. New York: The Penguin Press
Sachs, J. D.: 2008b, ‘Primary Health for All’, Scientific American, January 2008
Sen, A. 1999. Development as Freedom. Oxford: Oxford University Press
Sen, A. 2006. Why Health Equity? In Anand, S., Peter, F., & Sen, A., (eds) Public Health, Ethics and Equity. Oxford: Oxford University Press
Solomon, R. 1992. Corporate Roles, Personal Values: An Aristotelian Approach to Business Ethics. Business Ethics Quarterly 2, 317–40
Spinaci, S., & Heymann, D., 2001. Communicable Disease and Disability of the Poor. Development 44(1), 66 f
Streeten, P. (1975). Vorwort. Myrdal, G. Das Wertproblem in der Sozialwissenschaft. 2nd edition. Bonn: Neue Gesellschaft
U.K. Department for International Development: 2006, Fact Sheet: Access to Medicines (London)
U.N. Development Program: 2005, Human Development Report 2005: International Cooperation at a Crossroads (Oxford University Press, Oxford)
U.N. Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health: 2007, ‘Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines’, Draft for Consultation. Geneva, 19 September 2007. http://www2.essex.ac.uk/human_rights_centre/rth/docs/PH%20draft%20guidelines%2019%20sept%202007.doc
von Foerster, H. 2003. Understanding understanding. New York: Springer
von Glasersfeld, E. 1995. Radical Constructivism. A Way of Knowing and Learning. London: Falmer Press
Watzlawick, P. (ed.): 1984, The Invented Reality: How do We Know What We Believe We Know? (W.W. Norton, New York)
Wettstein, F. 2005. From Causality to Capability. Towards a New Understanding of the Multinational Corporation’s Enlarged Global Responsibilities. Journal of Corporate Citizenship 19, 105–117
WHO: 2000, The World Health Report 2000. Health Systems: Improving Performance (World Health Organization, Geneva)
WHO: 2002a, 25 Questions and Answers on Health & Human Rights. Health & Human Rights Publication Series, No. 1. World Health Organization, Geneva
World Health Organization: 2002b, The Lancet 360(9343), 1347–1360
WHO: 2007, Everybody’s Business. Strengthening Health Systems to Improve Health Outcomes. WHO’s Framework for Action (World Health Organization, Geneva)
Winslow, C.-E. A.: 1951, The Cost of Sickness and the Price of Health (World Health Organization, Geneva)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leisinger, K.M. Corporate Responsibilities for Access to Medicines. J Bus Ethics 85 (Suppl 1), 3–23 (2009). https://doi.org/10.1007/s10551-008-9944-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10551-008-9944-4